April 2, 2008
Meda AB Files for European Approval of BEMA™ Fentanyl
Updated January 15, 2008
Combination of narcotic, oral lozenge could be used to treat pain caused by other ailments beyond cancer.
Updated November 2, 2007
Move to larger space made to accommodate more employees, company says.
Updated November 1, 2007
Morrisville-based company seeks FDA approval for ‘breakthrough cancer pain.’ BDSI hopes to launch sales in 2008.
September 10, 2007
RTP-based firm buys all U.S. rights to oral delivery method from QLT USA.
Updated September 5, 2007
Europe-based Meda pays Morrisville drug development firm $30M up front for North America rights. Meda had already secured European rights.
Updated July 3, 2007
BioDelivery Sciences International announced Monday that its June 28 pre-NDA meeting with the U.S. Food and Drug Administration regarding the company’s Phase III BEMA Fentanyl product went according to plan.
April 26, 2007
Triangle-based drug development firm reports effectiveness in use of breakthrough pain killer.
Updated April 10, 2007
Al Medwar, who once worked for Triangle Pharmaceuticals, joins BDSI from EMD Pharmaceuticals.
August 31, 2006
Morrisville-based BDSI says Clinical Development Capital sought to acquire rights to drug delivery technology now under trial. CDC seeks to terminate $7M investment.
August 4, 2006
Morrisville-based pharmaceutical company to receive $2.5 million upfront payment. BDSI also secures rights to delivery system in Europe, U.S. markets.
June 9, 2006
FDA spells out possible ways for company to win marketing approval. BDSI to evaluate costs, time needed for additional testing.
May 17, 2006
Drug development firm is testing means of delivering powerful pain reliever through oral patch.